TherapeuticsMD, Inc. (TXMD)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 40M 80M 120M Q3 '21: 90.9M Q4 '21: 87M Q1 '22: 86.4M Q2 '22: 92M Q3 '22: 66.9M Q4 '22: 116.8M Q1 '23: 97.9M Q2 '23: 69.8M Q3 '23: 69.4M Q4 '23: 1.3M Q1 '24: 1.2M Q2 '24: 996K Q3 '24: 1.6M Q4 '24: 1.8M Q1 '25: 1.8M Q2 '25: 2.6M Q3 '25: 2.8M Q4 '25: 3M Q1 '26: 3.4M Q2 '26: 3.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 30M 60M 90M Q1 '19: 13.4M Q2 '19: 14.9M Q3 '19: 34.4M Q4 '19: 43.3M Q1 '20: 49.7M Q2 '20: 51.1M Q3 '20: 44.9M Q4 '20: 48.9M Q1 '21: 54.5M Q2 '21: 67.1M Q3 '21: 71.2M Q4 '21: 68.1M Q1 '22: 67.4M Q2 '22: 48.5M Q3 '22: 28.4M Q4 '22: 83M Q1 '23: 69M Q2 '23: 69.4M Q3 '23: 69.4M Q4 '23: 1.3M Q2 '19 Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23

Operating Income TTM

-150M -100M -50M 0 50M 100M 150M Q3 '21: -139M Q4 '21: -139.8M Q1 '22: -128.4M Q2 '22: -108M Q3 '22: -82.6M Q4 '22: 1.2M Q1 '23: 16.4M Q2 '23: 28.8M Q3 '23: 41.5M Q4 '23: -8.5M Q1 '24: -7M Q2 '24: -7.3M Q3 '24: -6.7M Q4 '24: -5.7M Q1 '25: -5.9M Q2 '25: -3.8M Q3 '25: -3.5M Q4 '25: -4.4M Q1 '26: -3.8M Q2 '26: -4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-210M -140M -70M 0 70M 140M 210M Q3 '21: -171.5M Q4 '21: -172.4M Q1 '22: -182.1M Q2 '22: -27.1M Q3 '22: -8.7M Q4 '22: 112M Q1 '23: 157.4M Q2 '23: 42.7M Q3 '23: 68.3M Q4 '23: -10.3M Q1 '24: -7.4M Q2 '24: -6.1M Q3 '24: -3.3M Q4 '24: -2.2M Q1 '25: -2.1M Q2 '25: -459K Q3 '25: 302K Q4 '25: -569K Q1 '26: 179K Q2 '26: -217K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 7M 14M 21M Q4 '17: 2.6M Q1 '18: 2.6M Q2 '18: 2.4M Q3 '18: 2.4M Q4 '18: 2.7M Q1 '19: 2.9M Q2 '19: 3.7M Q3 '19: 4.4M Q4 '19: 6.3M Q1 '20: 8.3M Q2 '20: 11.4M Q3 '20: 13.3M Q4 '20: 16M Q1 '21: 17.9M Q2 '21: 17.7M Q3 '21: 19.7M Q4 '22: 1.4M Q1 '18 Q4 '18 Q3 '19 Q2 '20 Q1 '21 Q4 '22

Operating Cash Flow TTM

-150M -100M -50M 0 50M 100M 150M Q3 '21: -133.5M Q4 '21: -142.7M Q1 '22: -122.2M Q2 '22: -122.7M Q3 '22: -103.4M Q4 '22: 9.4M Q1 '23: 18.5M Q2 '23: 42.2M Q3 '23: 55.1M Q4 '23: -23.1M Q1 '24: -14.6M Q2 '24: -9.8M Q3 '24: -3.8M Q4 '24: 1.2M Q1 '25: 2.1M Q2 '25: 1M Q3 '25: 2.1M Q4 '25: 2.5M Q1 '26: 2.7M Q2 '26: 3.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-210M -140M -70M 0 70M 140M 210M Q4 '17: -76.2M Q1 '18: -75.3M Q2 '18: -82.2M Q3 '18: -99.6M Q4 '18: -107M Q1 '19: -125.8M Q2 '19: -152.2M Q3 '19: -145.3M Q4 '19: -168.2M Q1 '20: -168.9M Q2 '20: -173.5M Q3 '20: -180.3M Q4 '20: -159.7M Q1 '21: -159M Q2 '21: -129.6M Q3 '21: -133.7M Q4 '21: -142.7M Q1 '22: -122.2M Q2 '22: -122.8M Q3 '22: -103.4M Q1 '18 Q4 '18 Q3 '19 Q2 '20 Q1 '21 Q4 '21 Q3 '22

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 100M 200M 300M Q1 '20: 271.5M Q2 '20: 271.9M Q3 '20: 272.6M Q1 '21: 6.9M Q2 '21: 7.9M Q3 '21: 8.4M Q1 '22: 8.6M Q2 '22: 8.8M Q3 '22: 9.3M Q1 '23: 9.8M Q2 '23: 10.2M Q3 '23: 10.7M Q1 '24: 11.5M Q2 '24: 11.5M Q3 '24: 11.5M Q1 '25: 11.6K Q2 '25: 11.6M Q3 '25: 11.6M Q1 '26: 11.6K Q2 '26: 11.6M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-24.00 -16.00 -8.00 0.00 8.00 16.00 24.00 Q1 '20: -0.34 Q2 '20: -0.30 Q3 '20: -0.29 Q4 '20: -0.25 Q1 '21: -6.13 Q2 '21: -11.35 Q3 '21: -16.85 Q4 '21: -21.68 Q1 '22: -21.71 Q2 '22: -3.47 Q3 '22: -0.98 Q4 '22: 12.10 Q1 '23: 17.43 Q2 '23: 4.36 Q3 '23: 7.17 Q4 '23: -1.00 Q1 '24: -0.69 Q2 '24: -0.54 Q3 '24: -0.27 Q4 '24: -0.19 Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.